Cargando…
The continuum of ovarian response leading to BIRTH, a real world study of ART in Spain
BACKGROUND: The first biosimilar of recombinant follicle stimulating hormone (rFSH) launched in Europe was Bemfola® in 2014 following a clinical development programme demonstrating efficacy and safety to the satisfaction of the European Medicines Agency. Since then the increasing use of biosimilar r...
Autores principales: | Ferrando, Marcos, Coroleu, Buenaventura, Rodríguez-Tabernero, Luis, Barrenetxea, Gorka, Guix, Cristina, Sánchez, Fernando, Jenkins, Julian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388222/ https://www.ncbi.nlm.nih.gov/pubmed/32742711 http://dx.doi.org/10.1186/s40738-020-00081-4 |
Ejemplares similares
-
Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study
por: Barrenetxea, Gorka, et al.
Publicado: (2018) -
Assessment of the immunogenicity of gonadotrophins during controlled ovarian stimulation
por: Morte, Carles, et al.
Publicado: (2017) -
Serum progesterone screening for frozen embryo transfer: present and
future perspectives
por: Coroleu, Buenaventura, et al.
Publicado: (2019) -
Study of the Genetic Etiology of Primary Ovarian Insufficiency: FMR1 Gene
por: Barasoain, Maitane, et al.
Publicado: (2016) -
Presence of Adenomyosis Impairs Clinical Outcomes in Women Undergoing Frozen Embryo Transfer: A Retrospective Cohort Study
por: Sachs-Guedj, Noémie, et al.
Publicado: (2023)